Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Rapid Detection Method Developed for Polymyxin-Resistant Enterobacteria

By LabMedica International staff writers
Posted on 01 Jun 2016
Among the most clinically significant multidrug-resistant bacteria are carbapenemase-producing Enterobacteriaceae, yet these bacteria usually remain susceptible to polymyxins, so interest in polymyxins has been renewed worldwide.

A rapid test has been developed that detects glucose metabolization associated with bacterial growth in the presence of a defined concentration of colistin or polymyxin B. More...
The standard reference technique for determining susceptibility to polymyxins is broth microdilution, which requires fastidious attention and at least 24 hours to perform.

Microbiologists at the University of Fribourg (Switzerland) developed the rapid polymyxin Nordmann/Poirel (NP) test that detects bacterial growth in the presence of a defined concentration of a polymyxin. Bacterial growth detection (or absence) is based on carbohydrate metabolism. Acid formation associated with carbohydrate metabolism in Enterobacteriaceae can be observed through the color change of a pH indicator. This test is rapid taking less than two hours and easy to perform.

To evaluate the performance of the rapid polymyxin NP test, the team used 200 isolates collected from clinical samples worldwide. This collection included 135 Enterobacteriaceae isolates resistant to polymyxin: five isolates of intrinsically polymyxin-resistant species and 130 isolates of various enterobacterial species with acquired resistance to polymyxins. The rapid polymyxin NP test uses two reagents and solutions: stock solutions of polymyxins and rapid polymyxin NP solution.

The sensitivity and specificity of the rapid NP test were 99.3% and 95.4%, respectively, compared with the standard broth microdilution method. By reading the color change of the wells every hour, the scientists determined that final results were obtained two hours after incubation when the tray was incubated at 35 ± 2 °C under an ambient atmosphere. However, positive results with frank color change were obtained as early as one hour after incubation for Klebsiella spp. and Escherichia coli isolates. Half of the Enterobacter spp. isolates gave positive results within 60 minutes of incubation and the other half within 120 minutes.

The authors concluded that the new test is inexpensive, easy to perform, sensitive, specific, and can be completed in less than two hours. It could be useful in countries facing endemic spread of carbapenemase producers and for which polymyxins are last-resort drugs. The study was published in the June 2016 issue of the journal Emerging Infectious Diseases.

Related Links:
University of Fribourg



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Biomarker Algorithm Clarifies Uncertain Alzheimer’s Amyloid Status

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image

GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026

GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.